Company Overview and News

 
Alt Resources moving Bottle Creek project towards development

2018-08-24 proactiveinvestors.com.au
Alt Resources (ASX:ARS) CEO James Anderson introduces Proactive Investors to the Western Australia-focused gold exploration and emerging development company, and discusses in depth the flagship Mt Ida Gold Project and Bottle Creek gold mine.
ARS

 
Alt Resources going to market soon to raise cash for Bottle Creek project development

2018-08-24 proactiveinvestors.com.au
Alt Resources (ASX:ARS) CEO James Anderson introduces Proactive Investors to the Western Australia-focused gold exploration and emerging development company, and discusses in depth the flagship Mt Ida Gold Project and Bottle Creek gold mine.
ARS

 
Alt Resources completes second-phase drilling at Bottle Creek Gold Project

2018-08-02 proactiveinvestors.com.au
Alt Resources Ltd (ASX:ARS) has completed phase II reverse circulation (RC) drilling at its Bottle Creek Gold Project along the Mt Ida gold belt in Western Australia.
ARS

 
Alt Resources begins second-phase drilling at Bottle Creek Gold Project

2018-07-24 proactiveinvestors.com.au
Alt Resources Ltd (ASX:ARS) has begun the second round of reverse circulation (RC) drilling at its Bottle Creek project along the Mt Ida Gold Belt in Western Australia.
ARS

 
Latitude sells $2m gold project

2018-05-11 businessnews.com.au
West Perth-based Latitude Consolidated has agreed to sell its Mt Ida gold project near Leonora to Alt Resources in a cash an scrip deal worth $2 million.
ARS

 
Alt Resources drills significant gold zones at Southwark deposit

2018-05-01 proactiveinvestors.com.au
Alt Resources Ltd (ASX:ARS) has received encouraging initial gold drilling results from the Southwark deposit within its Bottle Creek Gold Project in Western Australia.
ARS

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ASX:ARS / ALT RESOURCES LIMITED on message board site Silicon Investor.

Drones, Autonomous Vehicles and Flying Cars Drones, Autonomous Vehicles and Flying Cars Drones, Autonomous Vehicles and Flying Cars Car Nut Corner: All About Cars Car Nut Corner: All About Cars Car Nut Corner: All About Cars
Sears Holdings Corp. Sears Holdings Corp. Sears Holdings Corp. Chicago Bears Fan Club Chicago Bears Fan Club Chicago Bears Fan Club
ClearStation...Goldman Sachs Trading Room in a Box? ClearStation...Goldman Sachs Trading Room in a Box? ClearStation...Goldman Sachs Trading Room in a Box? The Justa and Lars Honors Bob Brinker Investment Club Thread The Justa and Lars Honors Bob Brinker Investment Club Thread The Justa and Lars Honors Bob Brinker Investment Club Thread
Drinking Water - EPA and Arsenic Drinking Water - EPA and Arsenic Drinking Water - EPA and Arsenic Tarsier, Ltd. Tarsier, Ltd. Tarsier, Ltd.
SiliconInvestor All Stars Forum SiliconInvestor All Stars Forum SiliconInvestor All Stars Forum Doctor Benjamin Carson---world renouwn Doctor and 21st Centu Doctor Benjamin Carson---world renouwn Doctor and 21st Centu Doctor Benjamin Carson---world renouwn Doctor and 21st Centu